Gedea Biotech AB
8
0
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
An Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Vulvovaginal Candidiasis Compared With an Untreated Control Group
Role: lead
An Open Single-armed Investigation to Evaluate the Safety of pHyph Following a Prolonged Treatment Duration in Adult Women With Bacterial Vaginosis
Role: lead
Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
Role: lead
Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Role: lead
Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Role: lead
A Randomised, Partly-blinded Investigation to Evaluate the Clinical Performance and Safety of pHyph in Adult Women With Bacterial Vaginosis Compared With an Untreated Control Group
Role: lead
Clinical Performance and Safety of the Gedea Pessary in Adult Women With Bacterial Vaginosis
Role: lead
VVC Sampling Study for Analysis Validation
Role: lead
All 8 trials loaded